Jérôme Fayette
Université Claude Bernard Lyon 1(FR)Centre Léon Bérard(FR)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Head and Neck Cancer Studies, Gastrointestinal Tumor Research and Treatment, Gastrointestinal disorders and treatments, Lung Cancer Research Studies
Most-Cited Works
- → Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells(2018)1,151 cited
- → Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients(2022)63 cited
- → Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors(2022)19 cited
- → Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 trial.(2025)9 cited
- → Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03(2017)3 cited
- Traitement médical des tumeurs stromales gastro-intestinales localisées et avancées : standards thérapeutiques en 2006(2006)
- → Dose expansion data from iintune-1, a phase 1/2 study of the STING agonist dazostinag plus pembrolizumab as first-line (1L), in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (RM-SCCHN).(2025)1 cited
- → HNSCC and Immunotherapy: The Beginning of a Long Story(2019)1 cited
- → Tumeurs solides rares et transplantation d’organes(2010)
- « Thérapies moléculaires ciblées : l'exemple de l'Iressa® (ZD1839) / Targeting molecular therapy by Iressa® (ZD1839) »(2016)